Yu-mei Li
P.R. China
Zhenjiang, China
Zhenjiang, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 49 publications
GGT6 as a Prognostic Biomarker and Therapeutic Target in Melanoma Using an Information-theoretical Method.
Journal: Cancer genomics & proteomics
Published: April 15, 2026
Comment on: Combined transplantation of human umbilical cord mesenchymal stem cells and MEEK micrografts in rabbits: A long-term self-controlled study.
Journal: Burns : journal of the International Society for Burn Injuries
Published: February 11, 2026
Comment on: Characterization and analysis of the skin mycobiome in keloid: A case-control study.
Journal: Burns : journal of the International Society for Burn Injuries
Published: January 03, 2026
Multi-target actions of natural flavonoids in skin flap survival: Opportunities and challenges.
Journal: Burns : journal of the International Society for Burn Injuries
Published: December 24, 2025
From static pathology to dynamic immunity: immunological plasticity and histopathological remodeling in atopic dermatitis and psoriasis.
Journal: Frontiers in immunology
Published: December 18, 2025
A Quantitative Assessment of the Phagocytosis of Allogeneic and Xenogeneic Erythrocytes by Rat Macrophages In Vitro.
Journal: Journal of visualized experiments : JoVE
Published: September 08, 2025
Advancing skin organoids in dermatology: Current limitations and future horizons.
Journal: Journal of the American Academy of Dermatology
Published: August 10, 2025
The Potential of Macrophages for Skin Anti-aging.
Journal: Frontiers in bioscience (Landmark edition)
Published: March 09, 2025
Pathogenesis and regenerative therapy in vitiligo and alopecia areata: focus on hair follicle.
Journal: Frontiers in medicine
Published: October 12, 2024
Causes and therapeutic limitations of clinical alopecia and the advent of human pluripotent stem cell follicular transplantation.
Journal: Stem cell research & therapy
Published: September 21, 2024
Long-Term Efficacy and Safety of Stapokibart in Adults with Moderate-to-Severe Atopic Dermatitis: An Open-Label Extension, Nonrandomized Clinical Trial.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: June 16, 2024
Last Updated: 09/26/2026